Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Converting cancer mutations into therapeutic opportunities.

EMBO molecular medicine - 1 Sept 2009

O'Brien Tom, Stokoe David

Abstract excerpt

While the use of synthetic lethality has been around for decades in model organism studies, it has only recently been applied to cancer therapy and judging by recent results, with great success. Following on a recent paper that demonstrates the clinical application of this strategy (Fong et al, 2009), Chris Lord and Alan Ashworth further explore the approach and show that poly(ADP-ribose) polymerase (PARP)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Regulation, Neoplastic
Share to Methotrexate
Share to Antimetabolites, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MutS Homolog 2 Protein

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to PTEN Phosphohydrolase

Source

Open in PubMed Open full text

Identifiers

PMID: 20049732
DOI: 10.1002/emmm.200900044
PMCID: PMC3378146

Genes

MSH2
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Converting cancer mutations into therapeutic opportunities.PMID 20049732Read ↗

Synthetic lethality: exploiting the addiction of cancer to DNA repair.Semantic proximity Read ↗

Embracing synthetic lethality of novel anticancer therapies.Semantic proximity Read ↗

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.Semantic proximity Read ↗

A lethal combination for cancer cells: synthetic lethality screenings for drug discovery.Semantic proximity Read ↗

Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.Semantic proximity Read ↗

The power and the promise of synthetic lethality for clinical application in cancer treatmentSemantic proximity Read ↗

Synthetic lethality to overcome cancer drug resistance.Semantic proximity Read ↗

Synthetic Lethality‐Based Targets and Their Exploration in Tumour Combination StrategiesSemantic proximity Read ↗

Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.Semantic proximity Read ↗

Synthetic lethality: the road to novel therapies for breast cancer.Semantic proximity Read ↗

Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.Semantic proximity Read ↗

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.